Xiao Yan Chu


Affiliation: Merck Research Laboratories
Country: USA


  1. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther. 2013;94:126-41 pubmed publisher
    ..The critical scientific gaps and future research directions in this field are discussed. ..
  2. request reprint
    Chu X, Bleasby K, Yabut J, Cai X, Chan G, Hafey M, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007;321:673-83 pubmed
    ..However, the magnitude of interactions should be low, and the effects may not be clinically meaningful, due to the high safety margin of sitagliptin. ..
  3. Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, et al. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos. 2013;41:668-81 pubmed publisher
    ..The results from clinical drug-drug interaction studies conducted thus far are generally supportive of these conclusions. ..
  4. Chu X, Shih S, Shaw R, Hentze H, Chan G, Owens K, et al. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans. Drug Metab Dispos. 2015;43:851-63 pubmed publisher
    ..3-fold, respectively. In contrast to clinical findings, RIF did not significantly increase plasma exposure of either intravenous or orally administered ATV, indicating species differences in the rate-limiting elimination pathways. ..
  5. Chu X, Bleasby K, Chan G, Nunes I, Evers R. The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?. Drug Metab Dispos. 2016;44:1498-509 pubmed publisher
  6. Chu X, Chan G, Evers R. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. J Pharm Sci. 2017;106:2357-2367 pubmed publisher
  7. request reprint
    Chu X, Strauss J, Mariano M, Li J, Newton D, Cai X, et al. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther. 2006;317:579-89 pubmed
    ..In conclusion, Mrp2(-/-) mice are a new valuable tool to study the role of Mrp2 in drug disposition. ..
  8. Chu X, Liang Y, Cai X, Cuevas Licea K, Rippley R, Kassahun K, et al. Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters. Pharm Res. 2009;26:459-68 pubmed publisher
    ..Gaboxadol-O-glucuronide was transported by MRP4, but not MRP2.Conlusion. Gaboxadol could be taken up into the kidney by hOAT1 followed by glucuronidation and efflux of the conjugate into urine via MRP4. ..
  9. Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol. 2013;9:237-52 pubmed publisher
    ..These differences complicate cross-species extrapolations, which is important when attempting to predict human pharmacokinetics (PK) of drug candidates and assess risk for drug-drug interactions (DDIs)...